About 30 results found for searched term "D-3" (0.001 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1659 | Saracatinib | Src-bcr-Abl |
| AZD0530 | ||
| Saracatinib (AZD0530) is an orally active small molecule Src inhibitor. | ||
| M1662 | AZD8330 | MEK |
| ARRY-424704, ARRY-704 | ||
| AZD8330 (ARRY-424704) is a novel, selective, highly efficacious, uncompetitive MEK inhibitor with an IC50 of 7 nM. | ||
| M1667 | Sapitinib (AZD8931) | EGFR/HER2 |
| AZD-8931 | ||
| AZD8931 (Sapitinib) is an equipotent, reversible inhibitor of Signaling by EGFR, ERBB2 (HER2), and ERBB3 with IC50 of 4, 3, 4 nM respectively. | ||
| M1674 | BIBR 953 | Thrombopoietin/Thrombin |
| Dabigatran, Pradaxa; BIBR 953ZW | ||
| BIBR 953 (Dabigatran, Pradaxa) is an oral anticoagulant from the class of the direct thrombin inhibitors. | ||
| M1686 | Bortezomib (PS-341) | Proteasome |
| Velcade; PS-341; LDP 341; MG 341; NSC 681239 | ||
| Bortezomib (PS-341) is a highly selective proteasome inhibitor with a ki value of 6nM. | ||
| M1690 | CI-1040 | MEK |
| PD184352 | ||
| CI-1040 (PD184352) is a targeted signal transduction inhibitor of MEK with a ki value of 300nM in vitro. | ||
| M1696 | Cediranib | VEGFR/PDGFR |
| AZD2171; NSC-732208 | ||
| Cediranib (AZD2171) inhibited VEGFR2 and KDR phosphorylation with IC50s of 0.4 and 0.5 nM, respectively. | ||
| M1702 | DCC-2036 | Src-bcr-Abl |
| Rebastinib | ||
| DCC-2036 is an ABL inhibitor with IC50 of 0.8 and 2 nM for u-ABL1native and p-ABL1native, respectively. | ||
| M1703 | Deforolimus | mTOR |
| Ridaforolimus, AP23573, MK-8669 | ||
| Deforolimus (also known as AP23573 and MK-8669) is an investigational targeted and small-molecule mTOR inhibitor. *The compound is unstable in solutions, freshly prepared is recommended | ||
| M1725 | CUDC-305 | HSP |
| CUDC-305 is a heat shock protein 90 (HSP90) inhibitor of the novel imidazopyridine class. | ||
| M1733 | TG101348 | JAK |
| Fedratinib; SAR302503 | ||
| TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM. | ||
| M1749 | Gefitinib | EGFR/HER2 |
| ZD-1839, Iressa | ||
| Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. | ||
| M1763 | Mirdametinib (PD0325901) | MEK |
| Mirdametinib；PD325901 | ||
| Mirdametinib (PD0325901) is a highly potent and selective MEK inhibitor with an IC50 in C26 cells of 0.33nM. | ||
| M1781 | Adezmapimod (SB203580) | p38 MAPK |
| RWJ 64809; PB 203580; Adezmapimod | ||
| Adezmapimod (SB203580) is a P38 MAPK inhibitor with an IC50 of 0.3-0.5 μM, which is 10 times less selective than SAPK3(106T) and SAPK4(106T), and inhibits PKB phosphorylation with an IC50 of 3-5 μM. | ||
| M1790 | MGCD0103 | HDAC |
| Mocetinostat | ||
| MGCD0103 is a novel HDAC inhibitor, highly specific for classes I and IV HDACs, with IC50 of 0.15, 0.29 and 1.66 μM for HDAC 1, HDAC 2 and HDAC 3 respectively. | ||
| M1797 | Retigabine | Potassium Channel |
| Ezogabine; D2312; D-23129 | ||
| Retigabine is a KCNQ/Kv7 potassium channel activator which functions by enhancing potassium currents via stabilizing the open conformation of the Kv7.2-7.3 channels. | ||
| M1806 | PD 0332991 HCL | CDK |
| Palbociclib HCl | ||
| PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. | ||
| M1810 | AZD5438 | CDK |
| AZD 5438 | ||
| AZD5438 is a novel, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 (IC50 values are 16, 6 and 20 nM respectively). | ||
| M1839 | MDV3100 | Androgen Receptor |
| Enzalutamide; MDV-3100 | ||
| MDV3100 is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. | ||
| M1843 | BMS-790052 | HCV Protease |
| Daclatasvir; EBP 883 | ||
| BMS-790052 (Daclatasvir) is a first-in-class, nonstructural protein 5A (NS5A) replication complex inhibitor with an EC50 of 9-50 pM. | ||
| M1847 | Fostamatinib disodium | Syk |
| R788 Disodium; R-935788 Disodium | ||
| Fostamatinib disodium (R788, R-935788) is a potent, ATP-competitive and selective Syk (Spleen tyrosine kinase) inhibitor with IC50 of 41 nM. | ||
| M1873 | LDN-193189 | ALK |
| LDN193189 | ||
| LDN-193189 is a highly potent small molecule inhibitor of bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3. | ||
| M1875 | PD173074 | FGFR |
| PD173074 is a selective FGFR1 and FGFR3 inhibitor with IC50 values of 5, 21.5, ~100, 17600 and 19800 nM for FGFR3, FGFR1, VEGFR2, PDGFR and c-Src respectively. | ||
| M1880 | WY 14643 (Pirinixic Acid) | PPAR |
| Pirinixic Acid; NSC 310038 | ||
| WY 14643 (Pirinixic Acid) is a potent and selective, peroxisome proliferator-activated receptor-α (PPARα) agonist. | ||
| M1885 | Tipifarnib | Farnesyl Transferase |
| IND 58359; R115777 | ||
| Tipifarnib (IND 58359) inhibited Farnesitransferase (FTase) with an IC50 of 0.86 nM. Tipifarnib has potential antitumor activity. Tipifarnib can inhibit exosome release of tumor cells. | ||
| M1898 | Plerixafor (AMD3100) | CXCR |
| AMD3100; JM3100; ID791; AMD-3329 | ||
| Plerixafor (AMD3100) is a CXCR4 chemokine receptor antagonist. | ||
| M1905 | PD318088 | MEK |
| PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor. | ||
| M1943 | Canertinib | EGFR/HER2 |
| CI-1033, PD-183805 | ||
| Canertinib (CI-1033) is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (IC50 7 nM). | ||
| M1962 | Lenalidomide | TNF Receptor |
| Revlimid, CC-5013 | ||
| Lenalidomide is a thalidomide analog known to display TNF-α secretion inhibition and possesses immunomodulatory properties. | ||
| M1966 | Fulvestrant | Estrogen Receptor |
| ICI 182780; ZD 9238; ZM 182780 | ||
| Fulvestrant is a Estrogen receptor (ER) antagonist with IC50 of 0.094 nM. Fulvestrant can also induce autophagy and apoptosis, and has anti-tumor effect. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
